EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Combination immunotherapy for advanced bowel cancer approved for NHS in England June 16, 2021 Resource Round-Up: Let’s Win Pancreatic Cancer May 23, 2023 Predicting future breast cancer with precision March 22, 2021 Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... September 26, 2022 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib EMA Recommends Extending Indications for Decitabine / Cedazuridine EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant...
